Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Search

Page Path
HOME > Search
6 "Disease activity"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
IBD
Efficacy of serum leucine-rich alpha-2 glycoprotein in predicting findings of Crohn’s disease small bowel lesion in capsule endoscopy
Teppei Omori, Miki Koroku, Shun Murasugi, Ayumi Ito, Maria Yonezawa, Shinichi Nakamura, Katsutoshi Tokushige
Intest Res 2024;22(4):464-472.   Published online May 7, 2024
DOI: https://doi.org/10.5217/ir.2023.00139
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Small bowel capsule endoscopy (SBCE) is an evaluation method for small bowel (SB) lesions in Crohn’s disease (CD). However, the relationship between SBCE findings and the serological biomarker leucine-rich alpha-2 glycoprotein (LRG) remains unclear. We aimed to establish appropriate cutoff values of LRG to predict the presence of SB lesions in CD through SBCE.
Methods
Patients with CD with SB lesions who had undergone SBCE and LRG measurements 1 month before and after the SBCE were included. The LRG values for ulcers ≥0.5 cm and other inflammatory lesions noted in SBCE were determined using the Youden Index, and the sensitivity and specificity were calculated. Additionally, the correlation between the SBCE scores (CD Activity in Capsule Endoscopy) and LRG values was evaluated.
Results
Forty patients without active colorectal lesions were included in the study. When the cutoff value of LRG for SB ulcers ≥ 0.5 cm was set at 14 μg/mL, the sensitivity was 92.3%, specificity was 81.5%, positive predictive value (PPV) was 70.6%, and negative predictive value (NPV) was 95.7%. In contrast, an LRG cutoff value of 12 μg/mL without inflammatory findings had a sensitivity of 91.7%, specificity of 82.1%, PPV of 68.8%, and NPV of 95.8%. CD Activity in Capsule Endoscopy correlated well with LRG values (Spearman’s rank correlation coefficient ρ = 0.681, P< 0.001).
Conclusions
An LRG cutoff value of 14 μg/mL may be useful in predicting the presence of SB ulcers ≥ 0.5 cm, and an LRG cutoff value of 12 μg/mL may be useful in predicting the absence of SB inflammatory findings.

Citations

Citations to this article as recorded by  
  • Leucine-rich alpha-2 glycoprotein as a superior biomarker to C-reactive protein for detecting small bowel lesions in Crohn’s disease
    Masashi Ohno, Atsushi Nishida, Akinori Otsuki, Yoshihiro Yokota, Takayuki Imai, Shigeki Bamba, Osamu Inatomi
    World Journal of Gastrointestinal Endoscopy.2025;[Epub]     CrossRef
  • 1,840 View
  • 203 Download
  • 2 Web of Science
  • 1 Crossref
Close layer
Inflammatory Bowel Diseases
Efficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn’s disease
Sanchit Sharma, Arti Gupta, Saurabh Kedia, Samagra Agarwal, Namrata Singh, Sandeep Goyal, Saransh Jain, Vipin Gupta, Pabitra Sahu, Sudheer Kumar Vuyyuru, Bhaskar Kante, Raju Sharma, Rajesh Panwar, Peush Sahni, Govind Makharia, Vineet Ahuja
Intest Res 2021;19(3):291-300.   Published online May 26, 2020
DOI: https://doi.org/10.5217/ir.2019.09172
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Exclusive enteral nutrition (EEN), an established modality for pediatric Crohn’s disease (CD) is seldomly utilized in adults. The present study reports the outcome of EEN in adult CD patients at a tertiary care hospital in India.
Methods
This was a retrospective analysis of CD patients who received EEN as a sole modality/adjunct to other treatment. The primary and secondary outcomes changed in Crohn’s Disease Activity Index (CDAI), and clinical response (decline in CDAI > 70), respectively, at 4 and 8 weeks. Subgroup analysis evaluated response across different phenotypes, EEN formulations and prior treatment. Linear mixed effect model was created to assess the predictors of EEN response.
Results
Thirty-one CD patients received EEN over median duration of 4 weeks (range, 2–6 weeks). CDAI showed a significant improvement post EEN at 4 (baseline 290 [260–320] vs. 240 [180–280], P= 0.001) and 8 weeks (baseline 290 [260–320] vs. 186 [160–240], P= 0.001), respectively. The cumulative clinical response rates at 4 and 8 weeks were 37.3% and 80.4% respectively. The clinical response rates at 8 weeks across B1 (n = 4), B2 (n = 18) and B3 (n = 9) phenotypes were 50%, 78.8% and 100% respectively (log-rank test, P= 0.093). The response rates at 8 weeks with polymeric (n = 8) and semi-elemental diet (n = 23) were 75% and 82.6%% respectively (log-rank test, P= 0.49). Baseline CDAI (odds ratio, 1.008; 95% confidence interval, 1.002–1.017; P= 0.046) predicted response to EEN.
Conclusions
EEN was effective in inducing clinical response across different phenotypes of CD. Baseline disease activity remained the most important predictor of clinical response to EEN.

Citations

Citations to this article as recorded by  
  • Adjunct polymeric exclusive enteral nutrition helps achieve biochemical remission in active Crohn’s disease in adults irrespective of disease location and concomitant corticosteroid use
    Hellen Kuo, Katrina Tognolini, Rumbidzai Mutsekwa, Dheeraj Shukla, Laura Willmann, Hadi Moattar, Alexander Dorrington, Naveed Ishaq, Maneesha Bhullar, John Edwards, Waled Mohsen, Pradeep Kakkadasam Ramaswamy
    Frontline Gastroenterology.2025; 16(1): 3.     CrossRef
  • Inflammatory bowel disease in south Asia: a scoping review
    Shabari Shenoy, Anuraag Jena, Carrie Levinson, Vishal Sharma, Parakkal Deepak, Tina Aswani-Omprakash, Shaji Sebastian, Jean-Frederic Colombel, Manasi Agrawal
    The Lancet Gastroenterology & Hepatology.2025; 10(3): 259.     CrossRef
  • Progress and Clinical Applications of Crohn’s Disease Exclusion Diet in Crohn’s Disease
    Duo Xu, Ziheng Peng, Yong Li, Qian Hou, Yu Peng, Xiaowei Liu
    Gut and Liver.2024; 18(3): 404.     CrossRef
  • Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline
    Andreas Sturm, Raja Atreya, Dominik Bettenworth, Bernd Bokemeyer, Axel Dignass, Robert Ehehalt, Christoph-Thomas Germer, P. C. Grunert, Ulf Helwig, Karoline Horisberger, Klaus Herrlinger, Peter Kienle, Torsten Kucharzik, Jost Langhorst, Christian Maaser,
    Zeitschrift für Gastroenterologie.2024; 62(08): 1229.     CrossRef
  • Refractory Crohn’s Disease: Perspectives, Unmet Needs and Innovations
    Luisa Bertin, Martina Crepaldi, Miriana Zanconato, Greta Lorenzon, Daria Maniero, Caterina De Barba, Erica Bonazzi, Sonia Facchin, Marco Scarpa, Cesare Ruffolo, Imerio Angriman, Andrea Buda, Fabiana Zingone, Edoardo Vincenzo Savarino, Brigida Barberio
    Clinical and Experimental Gastroenterology.2024; Volume 17: 261.     CrossRef
  • Use of oral diet and nutrition support in management of stricturing and fistulizing Crohn's disease
    Kush Fansiwala, Neha D. Shah, Kelly A. McNulty, Mary R. Kwaan, Berkeley N. Limketkai
    Nutrition in Clinical Practice.2023; 38(6): 1282.     CrossRef
  • Exclusive Enteral Nutrition Orchestrates Immunological Balances as Early as Week 4 in Adult Patients of Crohn’s Disease: A Pilot, Open-Lable Study
    Na Diao, Xinyu Liu, Minzhi Lin, Qingfan Yang, Bingyang Li, Jian Tang, Ni Ding, Xiang Gao, Kang Chao
    Nutrients.2023; 15(24): 5091.     CrossRef
  • Exclusive enteral nutrition with oral polymeric diet helps in inducing clinical and biochemical remission in adults with active Crohn's disease
    Pradeep Kakkadasam Ramaswamy
    Journal of Parenteral and Enteral Nutrition.2022; 46(2): 423.     CrossRef
  • Is the frequency of dietitian support associated with greater clinical improvements in adults with Crohn's disease undertaking exclusive enteral nutrition?
    Liz Purcell, Rumbidzai Mutsekwa, Rebecca Angus, Dheeraj Shukla, Michelle Palmer
    Journal of Human Nutrition and Dietetics.2022; 35(3): 435.     CrossRef
  • Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004
    Andreas Sturm, Raja Atreya, Dominik Bettenworth, Bernd Bokemeyer, Axel Dignaß, Robert Ehehalt, Christoph Germer, Philip C. Grunert, Ulf Helwig, Klaus Herrlinger, Peter Kienle, Martin E. Kreis, Torsten Kucharzik, Jost Langhorst, Christian Maaser, Johann Oc
    Zeitschrift für Gastroenterologie.2022; 60(03): 332.     CrossRef
  • Diet and nutrition in the management of inflammatory bowel disease
    Pabitra Sahu, Saurabh Kedia, Vineet Ahuja, Rakesh K. Tandon
    Indian Journal of Gastroenterology.2021; 40(3): 253.     CrossRef
  • Review of exclusive enteral therapy in adult Crohn’s disease
    Nikola Mitrev, Hin Huang, Barbara Hannah, Viraj Chandana Kariyawasam
    BMJ Open Gastroenterology.2021; 8(1): e000745.     CrossRef
  • Current Use of EEN in Pre-Operative Optimisation in Crohn’s Disease
    Sharafaath Shariff, Gordon Moran, Caris Grimes, Rachel Margaret Cooney
    Nutrients.2021; 13(12): 4389.     CrossRef
  • Exclusive Enteral Nutrition in Adult Crohn’s Disease: an Overview of Clinical Practice and Perceived Barriers
    Roberto de Sire, Olga Maria Nardone, Anna Testa, Giulio Calabrese, Anna Caiazzo, Fabiana Castiglione
    Clinical and Experimental Gastroenterology.2021; Volume 14: 493.     CrossRef
  • Making Decisions about Dietary Therapy in Inflammatory Bowel Disease
    Sydney Solomon, Eunie Park, Joseph A. Picoraro
    Gastrointestinal Disorders.2020; 2(4): 353.     CrossRef
  • EEN Yesterday and Today … CDED Today and Tomorrow
    Marta Herrador-López, Rafael Martín-Masot, Víctor Manuel Navas-López
    Nutrients.2020; 12(12): 3793.     CrossRef
  • 7,688 View
  • 312 Download
  • 17 Web of Science
  • 16 Crossref
Close layer
Review
IBD
Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn’s disease?: a systematic review
Ebby George Simon, Richard Wardle, Aye Aye Thi, Jeanette Eldridge, Sunil Samuel, Gordon William Moran
Intest Res 2019;17(2):160-170.   Published online February 7, 2019
DOI: https://doi.org/10.5217/ir.2018.00114
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Fecal calprotectin (FC) is a highly sensitive disease activity biomarker in inflammatory bowel disease. However, there are conflicting reports on whether the diagnostic accuracy in Crohn’s disease is influenced by disease location. The aim of this study was to undertake a systematic review of the published literature. Relevant databases were searched from inception to November 8, 2016 for cohort and case control studies which had data on FC in patients with isolated small bowel (SB) and large bowel (LB) Crohn’s disease. Reference standards for disease activity were endoscopy, magnetic resonance imaging, computed tomography or a combination of these. The QUADAS-2 research tool was used to assess the risk of bias. There were 5,619 records identified at initial search. The 2,098 duplicates were removed and 3,521 records screened. Sixty-one full text articles were assessed for eligibility and 16 studies were included in the final review with sensitivities and specificities per disease location available from 8 studies. Sensitivities of FC at SB and LB locations ranged from 42.9% to 100% and 66.7% to 100% respectively while corresponding specificities were 50% to 100% and 28.6% to 100% respectively. The sensitivities and specificities of FC to accurately measure disease activity in Crohn’s disease at different disease locations are diverse and no firm conclusion can be made. Better studies need to be undertaken to categorically answer the effect of disease location on the diagnostic accuracy of FC.

Citations

Citations to this article as recorded by  
  • Unravelling metabolite-microbiome interactions in inflammatory bowel disease through AI and interaction-based modelling
    Rebecca Hodgkiss, Animesh Acharjee
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2025; 1871(3): 167618.     CrossRef
  • Development of a capsule endoscopy scoring system for the early diagnosis of small bowel Crohn’s disease
    Yuya Ogino, Kento Sadashima, Yuichiro Yoshida, Hironobu Takedomi, Nanae Tsuruoka, Yasuhisa Sakata, Ayako Takamori, Tadakazu Hisamatsu, Takayuki Matsumoto, Motohiro Esaki
    Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Serum food specific IgG antibodies are associated with small bowel inflammation in patients with Crohn’s disease
    Jintong Chen, Huaning Chen, Yanni Huang, Hongchai Xie, Silin Li, Chengdang Wang
    European Journal of Clinical Nutrition.2024; 78(1): 48.     CrossRef
  • Combination of leucine-rich alpha-2 glycoprotein and fecal markers detect Crohn’s disease activity confirmed by balloon-assisted enteroscopy
    Ami Kawamoto, Kento Takenaka, Shuji Hibiya, Yoshio Kitazume, Hiromichi Shimizu, Toshimitsu Fujii, Eiko Saito, Kazuo Ohtsuka, Ryuichi Okamoto
    Intestinal Research.2024; 22(1): 65.     CrossRef
  • Which biomarkers best reflect the degree of inflammation in Crohn’s disease?
    Jihye Park
    Intestinal Research.2024; 22(1): 1.     CrossRef
  • RNA Expression of MMP12 Is Strongly Associated with Inflammatory Bowel Disease and Is Regulated by Metabolic Pathways in RAW 264.7 Macrophages
    Laura Arosa, Miguel Camba-Gómez, Luis Francisco Lorenzo-Martín, Laura Clavaín, Miguel López, Javier Conde-Aranda
    International Journal of Molecular Sciences.2024; 25(6): 3167.     CrossRef
  • Circulatory resistin levels in inflammatory bowel disease: a systematic review and meta-analysis
    Amir Hossein Behnoush, Seyede Parmis Maroufi, Tara Reshadmanesh, Yasmin Mohtasham Kia, Mitra Norouzi, Seyedeh Mina Mohammadi, Aleksandra Klisic, Amirmohammad Khalaji
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study
    Kyuwon Kim, Jae Jun Park, Hyuk Yoon, Jun Lee, Kyeong Ok Kim, Eun Sun Kim, Su Young Kim, Sun‐Jin Boo, Yunho Jung, Jun Hwan Yoo, Sung Wook Hwang, Sang Hyoung Park, Suk‐Kyun Yang, Byong Duk Ye
    Alimentary Pharmacology & Therapeutics.2024; 59(12): 1539.     CrossRef
  • Fecal Calprotectin in Patients with Crohn’s Disease: A Study Based on the History of Bowel Resection and Location of Disease
    Jeongkuk Seo, Subin Song, Seung Hwan Shin, Suhyun Park, Seung Wook Hong, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sung Wook Hwang
    Diagnostics.2024; 14(8): 854.     CrossRef
  • Utility of the Endoscopic Healing Index in Identifying Active Inflammation in Patients with Crohn’s Disease: Real World Data from a Tertiary Center
    Nathaniel A. Cohen, Tenzin Choden, Emma C. Dyer, Nicole M. Garcia, Natalie K. Choi, David T. Rubin
    Digestive Diseases and Sciences.2024; 69(8): 2955.     CrossRef
  • Diagnostic Value of Quantitative Contrast‐Enhanced Ultrasound in Comparison to Endoscopy in Children With Crohn's Disease
    Slavojka Ponorac, Raja Dahmane Gošnak, Darja Urlep, Damjana Ključevšek
    Journal of Ultrasound in Medicine.2023; 42(1): 193.     CrossRef
  • Resistin, Elastase, and Lactoferrin as Potential Plasma Biomarkers of Pediatric Inflammatory Bowel Disease Based on Comprehensive Proteomic Screens
    Anto Sam Crosslee Louis Sam Titus, Kamala Vanarsa, Sanam Soomro, Anjali Patel, Jarod Prince, Subra Kugathasan, Chandra Mohan
    Molecular & Cellular Proteomics.2023; 22(2): 100487.     CrossRef
  • Fecal immunochemical test for haemoglobin versus fecal calprotectin to monitoring endoscopic activity in inflammatory bowel disease
    Patricia Latorre Añó, Jorge Torrente Sánchez, Amparo Almudena Pérez Ibañez, Jose María Tenias Burillo, Nadia Paloma Moreno Sánchez, Antonio López-Serrano, Eduardo Moreno Osset, Julián Murado Pardo, José María Paredes
    Revista Española de Enfermedades Digestivas.2023;[Epub]     CrossRef
  • Clinical Value of Detecting Fecal Calprotectin by Using Colloidal Gold Assay in Screening or Diagnosing Crohn’s Disease
    Wangdong Zhang, Yanyun Fan, Meijun Chen, Tatsuya Toyokawa
    Gastroenterology Research and Practice.2023; 2023: 1.     CrossRef
  • AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Crohn’s Disease
    Ashwin N. Ananthakrishnan, Jeremy Adler, Karen A. Chachu, Nghia H. Nguyen, Shazia M. Siddique, Jennifer M. Weiss, Shahnaz Sultan, Fernando S. Velayos, Benjamin L. Cohen, Siddharth Singh
    Gastroenterology.2023; 165(6): 1367.     CrossRef
  • Amplification of an Electrochemiluminescence-Emissive Aptamer into DNA Nanotags for Sensitive Fecal Calprotectin Determination
    Fujin Lv, Jialiang Chen, Ying Wan, Jingyi Si, Meiyan Song, Fulin Zhu, Songyuan Du, Yuzhe Shang, Tiantian Man, Longyi Zhu, Kewei Ren, Yuhao Piao, Changfeng Zhu, Sheng-Yuan Deng
    Analytical Chemistry.2023; 95(50): 18564.     CrossRef
  • Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents
    Yoo Min Lee, Sujin Choi, Byung-Ho Choe, Hyo-Jeong Jang, Seung Kim, Hong Koh, Eun Sil Kim, Mi Jin Kim, Yon Ho Choe, Ben Kang
    Gut and Liver.2022; 16(1): 62.     CrossRef
  • Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis
    Su Bum Park, Seong-Jung Kim, Jun Lee, Yoo Jin Lee, Dong Hoon Baek, Geom Seog Seo, Eun Soo Kim, Sang-Wook Kim, So Yeong Kim
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Fungi
    Jane Alookaran, Yuying Liu, Thomas A. Auchtung, Amirali Tahanan, Manouchehr Hessabi, Parisa Asgarisabet, Mohammad H. Rahbar, Nicole Y. Fatheree, Deborah A. Pearson, Rosleen Mansour, Melissa R. Van Arsdall, Fernando Navarro, J. Marc Rhoads
    Journal of Pediatric Gastroenterology and Nutrition.2022; 74(3): 377.     CrossRef
  • Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn’s disease in clinical remission: a pilot study
    Sun-Ho Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
    Intestinal Research.2022; 20(2): 203.     CrossRef
  • Ultrasonographic scores for ileal Crohn’s disease assessment: Better, worse or the same as contrast-enhanced ultrasound?
    M. Freitas, F. Dias de Castro, V. Macedo Silva, C. Arieira, T. Cúrdia Gonçalves, S. Leite, M. J. Moreira, J. Cotter
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn’s disease
    Michael Logan, Mary MacKinder, Clare Martha Clark, Aikaterini Kountouri, Mwansa Jere, Umer Zeeshan Ijaz, Richard Hansen, Paraic McGrogan, Richard K. Russell, Konstantinos Gerasimidis
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Usefulness of ultrasonography for small intestinal evaluations in pediatric Crohn's disease
    Takeru Okuhira, Atsushi Yoden, Emiri Kaji, Masano Otani‐Akamatsu, Keisuke Inoue, Tomoki Aomatsu, Kimitaka Takitani, Akira Ashida
    Pediatrics International.2022;[Epub]     CrossRef
  • Intestinal ultrasonography and fecal calprotectin for monitoring inflammation of ileal Crohn’s disease: two complementary tests
    José María Paredes, Tomás Ripollés, Ángela Algarra, Rafael Diaz, Nadia Moreno, Patricia Latorre, María Jesús Martínez, Pilar Llopis, Antonio López, Eduardo Moreno-Osset
    Intestinal Research.2022; 20(3): 361.     CrossRef
  • Fecal calprotectin predicts endoscopic activity and mucosal healing of small bowel Crohn’s disease evaluated by double-balloon endoscopy
    Wei Han, Juan Wu, Peipei Zhang, Naizhong Hu, Qiao Mei, Jing Hu
    International Journal of Colorectal Disease.2022; 37(9): 1953.     CrossRef
  • Fecal Calprotectin for Small Bowel Crohn’s Disease: Is It a Cutoff Issue?
    Cristina Romero-Mascarell, Gloria Fernández-Esparrach, Cristina Rodríguez-De Miguel, Maria Carme Masamunt, Sonia Rodríguez, Jordi Rimola, Miguel Urpí, Gherzon Simon Casanova, Ingrid Ordás, Elena Ricart, Berta Caballol, Agnès Fernández-Clotet, Julià Panés,
    Diagnostics.2022; 12(9): 2226.     CrossRef
  • A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities
    Ferdinando D’Amico, Stéphane Nancey, Silvio Danese, Laurent Peyrin-Biroulet
    Journal of Crohn's and Colitis.2021; 15(1): 152.     CrossRef
  • The utility of faecal and urine biomarkers for small bowel diseases
    M.S. Ismail, Serhiy Semenov, Deirdre McNamara
    Current Opinion in Gastroenterology.2021; 37(3): 284.     CrossRef
  • Predicting disease course in ulcerative colitis using stool proteins identified through an aptamer-based screen
    Sanam Soomro, Suresh Venkateswaran, Kamala Vanarsa, Marwa Kharboutli, Malavika Nidhi, Ramya Susarla, Ting Zhang, Prashanth Sasidharan, Kyung Hyun Lee, Joel Rosh, James Markowitz, Claudia Pedroza, Lee A. Denson, Jeffrey Hyams, Subra Kugathasan, Chandra Moh
    Nature Communications.2021;[Epub]     CrossRef
  • Anti-Microbial Antibody Response is Associated With Future Onset of Crohn’s Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk
    Sun-Ho Lee, Williams Turpin, Osvaldo Espin-Garcia, Juan Antonio Raygoza Garay, Michelle I. Smith, Haim Leibovitzh, Ashleigh Goethel, Dan Turner, David Mack, Colette Deslandres, Maria Cino, Guy Aumais, Remo Panaccione, Kevan Jacobson, Alain Bitton, A. Hill
    Gastroenterology.2021; 161(5): 1540.     CrossRef
  • Diagnostic Accuracy of Fecal Calprotectin for the Detection of Small Bowel Crohn's Disease through Capsule Endoscopy: An Updated Meta-Analysis and Systematic Review
    Eun Suk Jung, Sang Pyo Lee, Sea Hyub Kae, Jung Han Kim, Hyeong Su Kim, Hyun Joo Jang
    Gut and Liver.2021; 15(5): 732.     CrossRef
  • Optimal Cutoff Level of Fecal Calprotectin for Detecting Small Bowel Inflammation in Crohn's Disease
    Eun Soo Kim
    Gut and Liver.2021; 15(5): 637.     CrossRef
  • Diagnostic Accuracy of Non-Invasive Imaging for Detection of Colonic Inflammation in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
    Meshari T. Alshammari, Rebecca Stevenson, Buraq Abdul-Aema, Guangyong Zou, Vipul Jairath, Shellie Radford, Luca Marciani, Gordon W. Moran
    Diagnostics.2021; 11(10): 1926.     CrossRef
  • Közös felelősség a gyulladásos bélbetegség diagnosztikájában és kezelésében.
    Dóra Dohos, Adrienn Erős, Kata Szemes, Patrícia Sarlós
    Orvosi Hetilap.2021; 162(33): 1311.     CrossRef
  • Crohn's Disease Activity Quantified by Iodine Density Obtained From Dual-Energy Computed Tomography Enterography
    Bari Dane, Sean Duenas, Joseph Han, Thomas O'Donnell, Justin Ream, Shannon Chang, Alec Megibow
    Journal of Computer Assisted Tomography.2020; 44(2): 242.     CrossRef
  • Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases
    Gerard Honig, Caren Heller, Andrés Hurtado-Lorenzo
    Inflammatory Bowel Diseases.2020; 26(10): 1451.     CrossRef
  • Multiomic features associated with mucosal healing and inflammation in paediatric Crohn’s disease
    Henry Taylor, Jose Ivan Serrano‐Contreras, Julie A. K. McDonald, Jenny Epstein, JM Fell, Rocio C. Seoane, Jia V. Li, Julian R. Marchesi, Ailsa L. Hart
    Alimentary Pharmacology & Therapeutics.2020; 52(9): 1491.     CrossRef
  • Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease
    Shan-Shan Gong, Yi-Hong Fan, Qing-Qing Han, Bin Lv, Yi Xu
    World Journal of Gastroenterology.2019; 25(18): 2240.     CrossRef
  • Clinical value of fecal calprotectin
    Amanda Ricciuto, Anne M. Griffiths
    Critical Reviews in Clinical Laboratory Sciences.2019; 56(5): 307.     CrossRef
  • 13,932 View
  • 315 Download
  • 42 Web of Science
  • 39 Crossref
Close layer
Original Article
IBD
Vitamin D deficiency is associated with disease activity in patients with Crohn’s disease
Kyoung Ho Ko, You Sun Kim, Bo Kyung Lee, Jong Hyun Choi, Yong Moon Woo, Jin Young Kim, Jeong Seop Moon
Intest Res 2019;17(1):70-77.   Published online October 10, 2018
DOI: https://doi.org/10.5217/ir.2018.00022
AbstractAbstract PDFPubReaderePub
Background/Aims
Previous data suggest that vitamin D has a significant role in inflammatory bowel disease (IBD). We investigated the incidence of vitamin D deficiency in Korean patients with IBD and the correlation between serum vitamin D level and disease activity.
Methods
We retrospectively analyzed the medical records of patients with IBD whose serum vitamin D levels were checked. Deficiency of 25-hydroxyvitamin D was defined as <20 ng/mL. Disease activity was evaluated using the partial Mayo score for ulcerative colitis (≥2 defined as active disease) and Harvey-Bradshaw index for Crohn’s disease (≥4 defined as active disease).
Results
We enrolled 87 patients with IBD (ulcerative colitis [UC], 45; Crohn’s disease [CD], 42). Among them, 65.5% (57/87) were men, with a mean age of 44.9±15.1 years (range, 18–75 years). The mean duration of disease was 4.7±4.8 years (range, 0.1–17.1 years). Vitamin D deficiency was found in 73.6% (64/87) of patients with IBD. Patients with IBD (mean vitamin D level, 16.3±9.0 ng/mL) showed lower vitamin D level than the healthy control group (mean vitamin D level, 20.4±7.0 ng/mL), with no statistically significant difference (P=0.136). Disease activity was inversely correlated with vitamin D deficiency in patients with CD (P=0.007). However, no correlation was observed in patients with UC (P=0.134).
Conclusions
Approximately 75% of Korean patients with IBD showed vitamin D deficiency state. Vitamin D deficiency is associated with disease activity, particularly in patients with CD.

Citations

Citations to this article as recorded by  
  • Correlation of Socioeconomic and Environmental Factors With Incidence of Crohn Disease in Children and Adolescents: Systematic Review and Meta-Regression
    Jens Weidner, Ingmar Glauche, Ulf Manuwald, Ivana Kern, Ines Reinecke, Franziska Bathelt, Makan Amin, Fan Dong, Ulrike Rothe, Joachim Kugler
    JMIR Public Health and Surveillance.2024; 10: e48682.     CrossRef
  • Micronutrient Deficiency and Muscular Status in Inflammatory Bowel Disease
    Joonhee Han, Hyun Joo Song, Min Sook Kang, Hogyung Jun, Heung Up Kim, Ki Soo Kang, Donghyoun Lee
    Nutrients.2024; 16(21): 3763.     CrossRef
  • Is Serum 25-Hydroxyvitamin D Level Associated with Severity of COVID-19? A Retrospective Study
    Munachimso Kizito Mbata, Mireille Hunziker, Anja Makhdoomi, Giorgia Lüthi-Corridori, Maria Boesing, Stéphanie Giezendanner, Jürgen Muser, Anne B. Leuppi-Taegtmeyer, Jörg D. Leuppi
    Journal of Clinical Medicine.2023; 12(17): 5520.     CrossRef
  • Genotype Prevalence of Lactose Deficiency, Vitamin D Deficiency, and the Vitamin D Receptor in a Chilean Inflammatory Bowel Disease Cohort: Insights from an Observational Study
    Tamara Pérez-Jeldres, M. Bustamante, Roberto Segovia-Melero, Nataly Aguilar, Fabien Magne, Gabriel Ascui, Denisse Uribe, Lorena Azócar, Cristián Hernández-Rocha, Ricardo Estela, Verónica Silva, Andrés De La Vega, Elizabeth Arriagada, Mauricio Gonzalez, Gi
    International Journal of Molecular Sciences.2023; 24(19): 14866.     CrossRef
  • The correlation between serum 25-hydroxyvitamin D level and ulcerative colitis: a systematic review and meta-analysis
    Chenyu Liu, Xin Liu, Haitao Shi, Fenrong Chen, Linlang Sun, Xin Gao, Yan Wang
    European Journal of Gastroenterology & Hepatology.2023; 35(12): 1375.     CrossRef
  • Prevalence and relevant factors of micronutrient deficiencies in hospitalized patients with inflammatory bowel disease
    Xiaojuan Li, Yedong Hu, Xiaodan Shi, Xinyan Zhu, Fei Liu
    Nutrition.2022; 99-100: 111671.     CrossRef
  • The Role of Vitamin D in Immune System and Inflammatory Bowel Disease
    Zengrong Wu, Deliang Liu, Feihong Deng
    Journal of Inflammation Research.2022; Volume 15: 3167.     CrossRef
  • Evaluation of nutritional status using bioelectrical impedance analysis in patients with inflammatory bowel disease
    Seung Hyuk Kim, You Sun Kim, Si Hyeong Lee, Hyun Mi Lee, Won Eui Yoon, Seo Hyun Kim, Hee Jun Myung, Jeong Seop Moon
    Intestinal Research.2022; 20(3): 321.     CrossRef
  • The Crosstalk between Vitamin D and Pediatric Digestive Disorders
    Cristina Oana Mărginean, Lorena Elena Meliț, Reka Borka Balas, Anca Meda Văsieșiu, Tudor Fleșeriu
    Diagnostics.2022; 12(10): 2328.     CrossRef
  • Intestinal vitamin D receptor signaling ameliorates dextran sulfate sodium‐induced colitis by suppressing necroptosis of intestinal epithelial cells
    Yongyan Shi, Xuewei Cui, Yanli Sun, Qun Zhao, Tianjing Liu
    The FASEB Journal.2020; 34(10): 13494.     CrossRef
  • Relationship Between Vitamin D Deficiency and Disease Activity in Patients with Inflammatory Bowel Disease in Ahvaz, Iran


    Esmat Rasouli, Narges Sadeghi, Abazar Parsi, Seyed Jalal Hashemi, Morteza Nayebi, Aliakbar Shayesteh
    Clinical and Experimental Gastroenterology.2020; Volume 13: 419.     CrossRef
  • Inflammatory Bowel Disease and Vitamin D
    Ki Bae Kim, Hyoung Woo Kim, Jun Su Lee, Soon Man Yoon
    The Korean Journal of Gastroenterology.2020; 76(6): 275.     CrossRef
  • Implications of the Westernized Diet in the Onset and Progression of IBD
    Fernando Rizzello, Enzo Spisni, Elisabetta Giovanardi, Veronica Imbesi, Marco Salice, Patrizia Alvisi, Maria Chiara Valerii, Paolo Gionchetti
    Nutrients.2019; 11(5): 1033.     CrossRef
  • Vitamin D deficiency associated with Crohn’s disease and ulcerative colitis: a meta-analysis of 55 observational studies
    Xi-Xi Li, Yang Liu, Jie Luo, Zhen-Dong Huang, Chao Zhang, Yan Fu
    Journal of Translational Medicine.2019;[Epub]     CrossRef
  • Vitamin D Deficiency is Associated with Increased Disease Activity in Patients with Inflammatory Bowel Disease
    Johannes Hausmann, Alica Kubesch, Mana Amiri, Natalie Filmann, Irina Blumenstein
    Journal of Clinical Medicine.2019; 8(9): 1319.     CrossRef
  • The Association of Disease Activity, BMI and Phase Angle with Vitamin D Deficiency in Patients with IBD
    Maria Chiara Mentella, Franco Scaldaferri, Marco Pizzoferrato, Antonio Gasbarrini, Giacinto Abele Donato Miggiano
    Nutrients.2019; 11(11): 2583.     CrossRef
  • 8,337 View
  • 306 Download
  • 19 Web of Science
  • 16 Crossref
Close layer
Focused Review: Intestinal Behçet's Disease
Optimal diagnosis and disease activity monitoring of intestinal Behçet's disease
Hyun Jung Lee, Jae Hee Cheon
Intest Res 2017;15(3):311-317.   Published online June 12, 2017
DOI: https://doi.org/10.5217/ir.2017.15.3.311
AbstractAbstract PDFPubReaderePub

Intestinal Behçet's disease (BD), generally accepted as a type of inflammatory bowel disease (IBD), could be diagnosed when patients with BD have objectively documented gastrointestinal symptoms and intestinal ulcerations. Similar to IBD, intestinal BD has an unpredictable disease course with relapse and remission and is often related to a poor prognosis. However, there is no single gold standard for assessment of the disease activity of intestinal BD, and its diagnosis and management depend heavily on expert opinions. The Korean IBD Study Group recently developed novel diagnostic criteria based on colonoscopy findings and clinical manifestations using a modified Delphi process to overcome drawbacks of previously used consensus for the diagnosis of intestinal BD. In addition, the recently developed disease activity index for intestinal BD, consisting of a relatively simple 8-point index, could also help in determining treatment strategies and monitoring therapeutic responses. In this review, the progress in the diagnosis and disease activity measurement of intestinal BD will be discussed.

Citations

Citations to this article as recorded by  
  • Predicting Factors of Long-term Outcome of Gastrointestinal Behçet's Disease: A Chinese Retrospective Study
    Xiaoman Zu, Shanshan Xiong, Yaming Lu, Ning Zhang, Shu Xu, Rui Feng, Baili Chen, Zhirong Zeng, Minhu Chen, Yao He
    Clinical Therapeutics.2024; 46(3): 201.     CrossRef
  • Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet’s disease
    Hye Kyung Hyun, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
    European Journal of Gastroenterology & Hepatology.2024; 36(4): 445.     CrossRef
  • Safety of Biologics and Small Molecules for Inflammatory Bowel Diseases in Organ Transplant Recipients
    Ga Hee Kim, Minjun Kim, Kyuwon Kim, Jung-Bin Park, Ji Eun Baek, June Hwa Bae, Seung Wook Hong, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
    Yonsei Medical Journal.2024; 65(5): 276.     CrossRef
  • Optimal Treatment Approaches to Intestinal Behçet's Disease Complicated by Myelodysplastic Syndrome: The KASID and KSBD Multicenter Study
    Jung-Bin Park, So Jung Han, Seung Bum Lee, Dong Hyun Kim, Jae Hee Cheon, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Soo Jung Park, Sang Hyoung Park
    Yonsei Medical Journal.2024; 65(5): 265.     CrossRef
  • Efficacy and Safety of Anti-Tumor Necrosis Factor-Alpha Agents for Patients with Intestinal Behcet’s Disease: A Systematic Review and Meta-Analysis
    Qingfeng Zhang, Chunyan Ma, Rongrong Dong, Weizhen Xiang, Meiqi Li, Zhenzhen Ma, Qingrui Yang
    Yonsei Medical Journal.2022; 63(2): 148.     CrossRef
  • Allogeneic stem cell transplantation for trisomy 8-positive myelodysplastic syndrome or myelodysplastic/myeloproliferative disease with refractory Behçet’s disease: Case report and the review of literature
    Takashi Onaka, Kazuhisa Nakano, Yuri Uemoto, Naoto Miyakawa, Yasuyuki Otsuka, Aiko Ogura-Kato, Fumie Iwai, Yoshiya Tanaka, Akihito Yonezawa
    Modern Rheumatology Case Reports.2022; 6(2): 273.     CrossRef
  • 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging Appearance of Gastrointestinal Behcet’s Disease
    Burak İnce, Ali Kibar, Sertaç Asa, Rabia Lebriz Uslu Beşli, Muhammet Sait Sağer, Ahmet Emre Eşkazan, Ali İbrahim Hatemi, Gülen Hatemi, Kerim Sönmezoğlu
    Molecular Imaging and Radionuclide Therapy.2022; 31(1): 57.     CrossRef
  • Clinical Course of Patients with Intestinal Behçet’s Disease According to Consensus-Based Diagnostic Categories
    Yu Young Joo, Bo-In Lee, Seung-Jun Kim, Han Hee Lee, Jin Su Kim, Jae Myung Park, Young-Seok Cho, Kang Moon Lee, Sang Woo Kim, Hwang Choi, Myung-Gyu Choi
    Gut and Liver.2022; 16(5): 746.     CrossRef
  • Femoral Vein Wall Thickness Measurement May Be a Distinctive Diagnostic Tool to Differentiate Behçet’s Disease with Intestinal Involvement and Crohn’s Disease
    Fatma Alibaz-Oner, Rabia Ergelen, Ilkay Ergenc, Gizem Seven, Ayten Yazıcı, Ayse Cefle, Cemal Bes, Ozlen Atug, Haner Direskeneli
    Digestive Diseases and Sciences.2021; 66(8): 2750.     CrossRef
  • Deep‐learning system for real‐time differentiation between Crohn's disease, intestinal Behçet's disease, and intestinal tuberculosis
    Jung Min Kim, Jun Gu Kang, Sungwon Kim, Jae Hee Cheon
    Journal of Gastroenterology and Hepatology.2021; 36(8): 2141.     CrossRef
  • Proteomic analysis-based discovery of a novel biomarker that differentiates intestinal Behçet’s disease from Crohn’s disease
    Jihye Park, Daeun Jeong, Youn Wook Chung, Seunghan Han, Da Hye Kim, Jongwook Yu, Jae Hee Cheon, Ji-Hwan Ryu
    Scientific Reports.2021;[Epub]     CrossRef
  • Behçet syndrome
    Yusuf Yazici, Gulen Hatemi, Bahram Bodaghi, Jae Hee Cheon, Noburu Suzuki, Nicola Ambrose, Hasan Yazici
    Nature Reviews Disease Primers.2021;[Epub]     CrossRef
  • C-reactive protein is associated with postoperative outcomes in patients with intestinal Behçet’s disease
    Eun Ae Kang, Jung Won Park, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Min Soo Cho, Jae Hee Cheon
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • Update on the Treatment of Behcet’s Disease of the Small Bowel with Biologic Agents
    Yehyun Park, Jae Hee Cheon
    Current Gastroenterology Reports.2020;[Epub]     CrossRef
  • A20 Haploinsufficiency in a Chinese Patient With Intestinal Behcet's Disease-Like Symptoms: A Case Report
    Yu Chen, Huanjun Huang, Yao He, Minhu Chen, Ursula Seidler, De'an Tian, Fang Xiao
    Frontiers in Immunology.2020;[Epub]     CrossRef
  • Association of Clinical Phenotypes in Haploinsufficiency A20 (HA20) With Disrupted Domains of A20
    Yu Chen, Zhenghao Ye, Liping Chen, Tingting Qin, Ursula Seidler, De'an Tian, Fang Xiao
    Frontiers in Immunology.2020;[Epub]     CrossRef
  • Behсet's disease: intestinal damage
    R. G. Goloeva, Z. S. Alekberova
    Rheumatology Science and Practice.2019; 56(6): 767.     CrossRef
  • Successful closure of ileostomy in a patient with intestinal Behçet's disease after therapy with adalimumab
    Zhe Yan, Bei-Bei Cui, Yong-Yang Yu, Geng Yin, Xiao-Min Cen, Qi-Bing Xie
    Medicine.2019; 98(9): e14624.     CrossRef
  • Intestinal manifestations of Behçet's disease
    R G Goloeva, Z S Alekberova, T A Lisitsyna, E A Stepanova, L P Orlova
    Terapevticheskii arkhiv.2019; 91(5): 111.     CrossRef
  • Cancer Risk in Patients with Intestinal Behçet’s Disease: A Nationwide Population-Based Study
    Minkyung Han, Yoon Suk Jung, Won Ho Kim, Jae Hee Cheon, Sohee Park
    Gut and Liver.2018; 12(4): 433.     CrossRef
  • Updated treatment strategies for intestinal Behçet’s disease
    Yong Eun Park, Jae Hee Cheon
    The Korean Journal of Internal Medicine.2018; 33(1): 1.     CrossRef
  • 9,980 View
  • 189 Download
  • 20 Web of Science
  • 21 Crossref
Close layer
Original Article
Circulating Ghrelin Levels and Obestatin/Ghrelin Ratio as a Marker of Activity in Ulcerative Colitis
Ja Young Jung, Ji Bong Jeong, Ji Won Kim, Su Hwan Kim, Seong-Joon Koh, Byeong Gwan Kim, Kook Lae Lee
Intest Res 2015;13(1):68-73.   Published online January 29, 2015
DOI: https://doi.org/10.5217/ir.2015.13.1.68
AbstractAbstract PDFPubReader
<b>Background/Aims</b><br/>

Ghrelin levels are known to increase in patients with ulcerative colitis (UC), but serum obestatin levels in UC patients are not well elucidated. The aim of this study was to examine the relationship between serum ghrelin and obestatin levels and disease activity in UC patients.

Methods

The serum ghrelin and obestatin levels were measured in 21 UC patients (12 with active disease and 9 in remission) using enzyme-linked immunosorbent assay. The relationship between the circulating levels of these 2 hormones and disease activity was analyzed. The colonic mucosal mRNA expression of ghrelin and obestatin was measured by quantitative reverse transcription polymerase chain reaction.

Results

The mean serum ghrelin values were significantly higher in patients with active disease than in patients with remission (1370.6±404.3 vs. 783.5±235.3 pg/mL, P=0.001). Colonic mucosal mRNA expression of ghrelin was also significantly higher in patients with active disease than in patients in remission (0.805±0.214 vs. 0.481±0.356, P=0.018). However, the mean serum obestatin levels and colonic mucosal mRNA expression of obestatin were not significantly different between both groups. The circulating obestatin/ghrelin ratio was significantly lower in patients with active UC than in patients in remission (0.32±0.08 vs. 0.58±0.20, P=0.001).

Conclusions

The serum ghrelin levels and the obestatin/ghrelin ratio were related to the activity of UC, but serum obestatin was not related to activity of UC. The ghrelin levels and the obestatin/ghrelin ratio could serve as activity markers in patients with UC.

Citations

Citations to this article as recorded by  
  • Unveiling the Ghrelin and Obestatin Roles in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis Assessing Their Pathogenic Implications and Biomarker Utility
    Amirmohammad Khalaji, Nastaran Babajani, Zahra Amirsardari, Behrad Saeedian, Soheil Peiman, Nathan A Berger, Amir Hossein Behnoush
    Inflammatory Bowel Diseases.2024; 30(4): 629.     CrossRef
  • Effects of Spirulina supplementation in patients with ulcerative colitis: a double-blind, placebo-controlled randomized trial
    Sajjad Moradi, Reza Bagheri, Parsa Amirian, Mahsa Zarpoosh, Neda Cheraghloo, Alexei Wong, Mehdi Zobeiri, Mohammad Hassan Entezari
    BMC Complementary Medicine and Therapies.2024;[Epub]     CrossRef
  • “Sibling” battle or harmony: crosstalk between nesfatin-1 and ghrelin
    Xi Chen, Jing Dong, Qian Jiao, Xixun Du, Mingxia Bi, Hong Jiang
    Cellular and Molecular Life Sciences.2022;[Epub]     CrossRef
  • Role of the Ghrelin System in Colitis and Hepatitis as Risk Factors for Inflammatory-Related Cancers
    Aldona Kasprzak, Agnieszka Adamek
    International Journal of Molecular Sciences.2022; 23(19): 11188.     CrossRef
  • Correlation between the tissue ghrelin presence, disease activity and laboratory parameters in ulcerative colitis patients; immunohistochemical study
    Memduh Sahin, Kivilcim Eren Erdogan, Emine Tekingündüz, Gernot Zissel
    PLOS ONE.2022; 17(11): e0276065.     CrossRef
  • l-Glutamine and Physical Exercise Prevent Intestinal Inflammation and Oxidative Stress Without Improving Gastric Dysmotility in Rats with Ulcerative Colitis
    Raisa de Oliveira Santos, Geovane da Silva Cardoso, Lara da Costa Lima, Mickael Laudrup de Sousa Cavalcante, Mariana Sousa Silva, Ana Karolina Martins Cavalcante, Juliana Soares Severo, Francisca Beatriz de Melo Sousa, Gabriella Pacheco, Even Herlany Pere
    Inflammation.2021; 44(2): 617.     CrossRef
  • Obestatin and Its Fragments: A New Approach to the Regulation of Body Weight under Normal and Pathological Conditions
    A. V. Graf, E. E. Khirazova, M. V. Maslova, N. A. Sokolova
    Moscow University Biological Sciences Bulletin.2020; 75(2): 50.     CrossRef
  • Ghrelin and gastrointestinal wound healing. A new perspective for colorectal surgery
    Humberto Fenner Lyra Junior, Igor Kunze Rodrigues, Leonardo de Lucca Schiavon, Armando José D`Acâmpora
    Acta Cirurgica Brasileira.2018; 33(3): 282.     CrossRef
  • TNF-α inhibits SCF, ghrelin, and substance P expressions through the NF-κB pathway activation in interstitial cells of Cajal
    Keyu Ren, Chunming Yong, Hao Yuan, Bin Cao, Kun Zhao, Jin Wang
    Brazilian Journal of Medical and Biological Research.2018;[Epub]     CrossRef
  • Biochemical properties and biological actions of obestatin and its relevence in type 2 diabetes
    Brian D. Green, David J. Grieve
    Peptides.2018; 100: 249.     CrossRef
  • Treatment with Obestatin—A Ghrelin Gene-Encoded Peptide—Reduces the Severity of Experimental Colitis Evoked by Trinitrobenzene Sulfonic Acid
    Katarzyna Konarska, Jakub Cieszkowski, Zygmunt Warzecha, Piotr Ceranowicz, Anna Chmura, Beata Kuśnierz-Cabala, Krystyna Gałązka, Paweł Kowalczyk, Andrzej Miskiewicz, Thomas Jan Konturek, Michał Pędziwiatr, Artur Dembiński
    International Journal of Molecular Sciences.2018; 19(6): 1643.     CrossRef
  • Serum Adipocytokine Levels as Surrogate Markers for Disease Activity of Crohn’s Disease
    Su Hwan Kim, Seung Hyeon Jang, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, You Sun Kim, Dong Soo Han, Joo Sung Kim
    The American Journal of the Medical Sciences.2017; 353(5): 439.     CrossRef
  • Function of obestatin in the digestive system
    Yue-Xian Xing, Liu Yang, Hong-Yu Kuang, Xin-Yuan Gao, Hao-Ling Liu
    Nutrition.2017; 34: 21.     CrossRef
  • NF-kappa B activation correlates with disease phenotype in Crohn’s disease
    Yoo Min Han, Jaemoon Koh, Ji Won Kim, Changhyun Lee, Seong-Joon Koh, ByeongGwan Kim, Kook Lae Lee, Jong Pil Im, Joo Sung Kim, Gernot Sellge
    PLOS ONE.2017; 12(7): e0182071.     CrossRef
  • The obestatin/ghrelin ratio and ghrelin genetics in adult celiac patients before and after a gluten-free diet, in irritable bowel syndrome patients and healthy individuals
    Francesco Russo, Guglielmina Chimienti, Michele Linsalata, Caterina Clemente, Antonella Orlando, Giuseppe Riezzo
    European Journal of Gastroenterology & Hepatology.2017; 29(2): 160.     CrossRef
  • Plasma ghrelin level and plasma ghrelin/obestatin ratio are related to intestinal metaplasia in elderly patients with functional dyspepsia
    Su Hwan Kim, Ji Won Kim, Junsu Byun, Ji Bong Jeong, Byeong Gwan Kim, Kook Lae Lee, Zane B Andrews
    PLOS ONE.2017; 12(4): e0175231.     CrossRef
  • Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes
    Elaine Cowan, Kerry J Burch, Brian D Green, David J Grieve
    British Journal of Pharmacology.2016; 173(14): 2165.     CrossRef
  • Obestatin Accelerates the Healing of Acetic Acid‐Induced Colitis in Rats
    Aleksandra Matuszyk, Piotr Ceranowicz, Zygmunt Warzecha, Jakub Cieszkowski, Joanna Bonior, Jolanta Jaworek, Beata Kuśnierz-Cabala, Peter Konturek, Tadeusz Ambroży, Artur Dembiński, Tanea T. Reed
    Oxidative Medicine and Cellular Longevity.2016;[Epub]     CrossRef
  • Ghrelin receptor modulates T helper cells during intestinal inflammation
    M. Di Giovangiulio, N. Stakenborg, G. Bosmans, E. Meroni, G. Farro, P. J. Gomez‐Pinilla, I. Depoortere, G. E. Boeckxstaens, G. Matteoli
    Neurogastroenterology & Motility.2015; 27(11): 1542.     CrossRef
  • 5,524 View
  • 36 Download
  • 21 Web of Science
  • 19 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP